![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
March 6, 2025
March 5, 2025
Posts
;
You may be eligible to participate in a clinical study that is testing the addition of #radiotherapy to #chemotherapy for patients with #EsophagealCancer and #StomachCancer. Learn more: https://bit.ly/ea2183 #esocsm #gicsm
Great work to @AllinaHealth / Abbott-Northwestern Hospital for enrolling their first patient in #ClinicalTrial EA5182! This study is exploring osimertinib +/- bevacizumab as initial treatment for pts with EGFR-mutant #LungCancer. Learn more: #lcsm
Trial Spotlight: Helena Yu Gives an Update on the EA5182 Trial for EGFR-Mutant Non-Small Cell Lung...
This phase 3 randomized controlled trial is comparing first-line treatment with osimertinib plus bevacizumab versus osim...
bit.ly
The EAQ211/@cancergenomics_ clinical study is evaluating the impact of social and genetic factors on outcomes in adolescent & young adult (#AYA) #cancer survivors. Learn more: https://bit.ly/eaq211-study #AYACancer #AYACSM
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
41
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
